Accounts Receivable, after Allowance for Credit Loss, Current in USD of Tonix Pharmaceuticals Holding Corp. from Q2 2024 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Tonix Pharmaceuticals Holding Corp. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and change rate from Q2 2024 to Q3 2025.
  • Tonix Pharmaceuticals Holding Corp. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Sep 2025 was $3,481,000, a 13% decline year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Tonix Pharmaceuticals Holding Corp. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $3,481,000 -$532,000 -13% 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $2,320,000 -$1,019,000 -31% 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $3,312,000 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $3,683,000 31 Dec 2024 10-Q 10 Nov 2025 2025 Q3
Q3 2024 $4,013,000 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q2 2024 $3,339,000 30 Jun 2024 10-Q 16 Aug 2024 2024 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.